IkT-148009 for Parkinson’s Disease

Disease-Modifying Therapy to Reverse the Course of Parkinson’s Disease

Our lead product candidate, IkT-148009, is a highly potent, first-in-class, small-molecule drug designed and engineered as a chronically administered, once-daily oral medication that targets an underlying biological mechanism that leads to Parkinson’s disease, with the goal of reversing disease progression. IkT-148009 is designed to block the activation of Abl kinase, a clinically validated drug target, to prevent and/or reverse the loss of dopamine-secreting neurons in the brain by restoring neuroprotective mechanisms.

Having demonstrated that Abl kinase inhibition can protect against disruption of development and progression of Parkinson’s-like syndrome in animal models using IkT-148009, we have received clearance from the FDA for two Investigational New Drug (IND) applications that enable direct-to-Phase-2 clinical studies to demonstrate proof of principle for IkT-148009’s mechanism of action in Parkinson’s disease, and we are currently completing IND-enabling studies to advance IkT-148009 directly into Parkinson’s disease patients.

Back to Top